Medicine in Black and White: BiDil®: Race and the Limits of Evidence-Based Medicine
Open Access
- 23 August 2006
- journal article
- Published by Oxford University Press (OUP) in Significance
- Vol. 3 (3) , 118-121
- https://doi.org/10.1111/j.1740-9713.2006.00181.x
Abstract
When the US Food and Drug Administration licensed the drug BiDil® in June 2005 it was hailed as a significant step towards “personalised prescribing”. This is because BiDil® had been patented, tested and approved for use by just one group of patients: those “of African descent”. George Ellison examines the statistical evidence that underpinned the development of BiDil® as a “racial drug” and finds it less than satisfactory.Keywords
This publication has 6 references indexed in Scilit:
- Statistics and the medicine of the futureSignificance, 2006
- ‘Population profiling’ and public health risk: When and how should we use race/ethnicity?Critical Public Health, 2005
- Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart FailureNew England Journal of Medicine, 2004
- Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trialsJournal of Cardiac Failure, 1999
- A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart FailureNew England Journal of Medicine, 1991
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986